

ProteoTech, Inc.
12040 115th Ave., NE
Kirkland, WA 98034
Office: (425) 823-0400
Fax: (425) 823-8508
E-mail: info@proteotech.com

Potential Promising Therapy for Systemic AA Amyloidosis disease
To date, there is no approved FDA for the treatment of this disease. Systebryl™ has shown great promise in lab testing and in vivo modeling. Lab research tests show that Systebryl™ has a positive effect in preventing and/or reducing AA amyloid fibril formation associated with Systemic AA Amyloidosis.
ProteoTech will continue to develop Systebryl™ and request Orphan Drug Status from the FDA with will provide extended patent protection due to smaller population of people afflicted with this disease. |